Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Disease Presentation and Remission Rate in Graves’ Disease Treated With Antithyroid Drugs: Is Gender Really a Factor?
source: Endocrine Practice
year: 2019
authors: Diker-Cohen T, Duskin-Bitan H, Shimon I, Hirsch D, Akirov A, Tsvetov G, Robenshtok E
summary/abstract:Objective:
Male gender is considered an adverse prognostic factor for remission of Graves disease treatment with antithyroid drugs (ATDs), although published data are conflicting. This often results in early consideration of radioiodine treatment and surgery for men. Our objective was to compare disease presentation and outcome in men versus women treated with ATDs.
Methods:
Retrospective study of 235 patients (64 men, 171 women) with Graves disease who were evaluated for features at presentation and outcome at the end of follow-up between 2010 and 2015.
Results:
Disease presentation was similar in men and women for age at diagnosis (41.4 ± 14 years vs. 40 ± 15 years), duration of follow-up (6.6 ± 7 years vs. 7.7 ± 6 years), rates of comorbid autoimmune diseases, and rate of Graves ophthalmopathy. Smoking was more prevalent in males (31% vs. 15%; P = .009). Free thyroxine and triiodothyronine levels were comparable. ATDs were first-line treatment in all males and in 168 of 171 females, for a median duration of 24 and 20 months, respectively ( P = .55). Remission rates were 47% in men and 58% in women ( P = .14). Males had fewer adverse events (9% vs. 18%) and treatment discontinuation (5% vs. 16%). Disease recurrence was comparable (14% vs. 20%; P = .32), as was requirement for second-line treatment, either radioiodine therapy or thyroidectomy.
Conclusion:
Graves disease presentation is similar in men and women. Men treated with ATDs have high remission rates and similar recurrence rates compared to women, with fewer adverse events and less discontinuation of treatment. ATDs are an attractive first-line treatment for both genders.
DOI: 10.4158/EP-2018-0365
read more full text
myBinderRelated Content
-
Relation Between Therapy for Hyperthyroidism and the Course of Graves’ OphthalmopathyBackground: The chief clinical characte...
-
Relation between Therapy Options for Graves’ Disease and the Course of Graves’ Ophthalmopathy: A Systema...Background: The relation between therap...
-
Management of Endocrine Disease: Arguments for the Prolonged Use of Antithyroid Drugs in Children With Graves’...Graves' disease is an autoimmune disorde...
-
Cost-Utility Analysis Comparing Radioactive Iodine, Anti-Thyroid Drugs and Total Thyroidectomy for Primary Treatment...Objective: Little data is in existence ...
-
Graves’ Disease Pharmacotherapy in Women of Reproductive AgeGraves' disease is an autoimmune disorde...
-
Remission of Graves’ Disease During Anti-Thyroid Drug Therapy: Time to Reconsider the Mechanism?Therapy of Graves' hyperthyroidism with ...
-
Current Trends in Antithyroid Drug Treatment of Graves’ DiseaseIntroduction: Graves' hyperthyroidism i...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Google